UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 12, 2016

 

 

Bionik Laboratories Corp.

(Exact Name of Registrant as Specified in Its Charter)

 

 

Delaware   000-54717   27-1340346
(State or Other Jurisdiction of Incorporation or Organization)   (Commission File Number)   (IRS Employer Identification No.)

 

 

483 Bay Street, N105

Toronto, ON

 

M5G 2C9

(Address of Principal Executive Offices)

  (Zip Code)

 

 

Registrant’s Telephone Number, Including Area Code: (416) 640-7887

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders

 

The Annual Meeting of Stockholders (the “Annual Meeting”) of Bionik Laboratories Corp. (the “Company”) was held on August 12, 2016. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. The proposals are described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on July 12, 2016.

 

Proposal 1:Election of the five nominees listed below to serve on the Board of Directors of the Company until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified:

 

Nominee

 

For

 

Withhold Authority

Peter Bloch   59,163,159   267,169
Michal Prywata   59,162,459   267,869
Hermano Igo Krebs   59,135,540   294,788
Robert Hariri   59,162,459   267,869
Marc Mathieu   59,037,459   392,869

 

Proposal 2:To approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split of its issued and outstanding common stock.

 

For

 

Against

 

Abstain

59,968,816   620,959   197,448

 

Proposal 3:To amend the Company’s 2014 Equity Incentive Plan to change the number of shares of common stock authorized thereunder for grant from 10,800,000 to 15% of the shares of common stock and Exchangeable Shares issued and outstanding, and increase certain award limits.

 

For

 

Against

 

Abstain

48,210,145   3,893,535   7,326,648

 

Proposal 4.To ratify MNP, LLP as the Company’s independent public accountants for the year ending March 31, 2017.

 

For

 

Against

 

Abstain

59,147,687   381,569   262,500

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 17, 2016

 

  BIONIK LABORATORIES CORP.  
       
       
  By: /s/ Leslie Markow  
  Name:  Leslie Markow  
  Title:  Chief Financial Officer